This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the official electronic version on GPO’s govinfo.gov.
The documents posted on this site are XML renditions of published Federal Register documents. Each document posted on the site includes a link to the corresponding official PDF file on govinfo.gov. This prototype edition of the daily Federal Register on FederalRegister.gov will remain an unofficial informational resource until the Administrative Committee of the Federal Register (ACFR) issues a regulation granting it official legal status. For complete information about, and access to, our official publications and services, go to About the Federal Register on NARA's archives.gov.
The OFR/GPO partnership is committed to presenting accurate and reliable regulatory information on FederalRegister.gov with the objective of establishing the XML-based Federal Register as an ACFR-sanctioned publication in the future. While every effort has been made to ensure that the material on FederalRegister.gov is accurately displayed, consistent with the official SGML-based PDF version on govinfo.gov, those relying on it for legal research should verify their results against an official edition of the Federal Register. Until the ACFR grants it official status, the XML rendition of the daily Federal Register on FederalRegister.gov does not provide legal notice to the public or judicial notice to the courts.
Food and Drug Administration, HHS.
Final rule.
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during May 2013. FDA is also informing the public of the availability of summaries the basis of approval and of environmental review documents, where applicable.
This rule is effective July 15, 2013.
George K. Haibel, Center for Veterinary Medicine (HFV-6), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-276-9019, ghaibel@fda.hhs.gov.
FDA is amending the animal drug regulations to reflect approval actions for NADAs and ANADAs during May 2013, as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA). These public documents may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. Persons with access to the Internet may obtain these documents at the CVM FOIA Electronic Reading Room: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofFoods/CVM/CVMFOIAElectronicReadingRoom/default.htm.
This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.
| NADA/ANADA | Sponsor | New animal drug product name | Action | 21 CFR section | FOIA summary | NEPA review |
|---|---|---|---|---|---|---|
| 141-279 | Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007 | NICARB 25% (nicarbazin) and BMD (bacitracin methylene disalicylate) Type A medicated articles | Supplement revising nicarbazin dosage to a range consistent with dosage approved for use in combination feeds | 558.366 | No | CE 1 |
| ( printed page 42007) | ||||||
| 141-345 | Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007 | APOQUEL (oclacitinib tablet) | Original approval for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age | 520.1604 | Yes | CE 1 |
| 200-544 | Huvepharma AD, 5th Floor, 3A Nikolay Haytov Str., 1113 Sophia, Bulgaria | ZILMAX (zilpaterol hydrochloride) plus RUMENSIN (monensin) plus TYLOVET 100 (tylosin phosphate) plus MGA (melengestrol acetate) Type A medicated articles | Original aapproval as a generic copy of NADA 141-280) | 528.665 | Yes | CE 1 |
| 1 The Agency has determined under 21 CFR 25.33 that this action is categorically excluded (CE) from the requirement to submit an environmental assessment or an environmental impact statement because it is of a type that does not individually or cumulatively have a significant effect on the human environment. | ||||||
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 520 and 558 are amended as follows:
1. The authority citation for 21 CFR part 520 continues to read as follows:
2. Add § 520.1604 to read as follows:
(a) Specifications. Each tablet contains 3.6, 5.4, or 16 milligrams (mg) of oclacitinib as oclacitinib maleate.
(b) Sponsor. See No. 054771 in § 510.600(c) of this chapter.
(c) Conditions of use —(1) Amount. Administer orally 0.18 to 0.27 mg/per pound of body weight (0.4 to 0.6 mg/kg body weight) twice daily for up to 14 days; then administered once daily for maintenance therapy.
(2) Indications for use. For control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
3. The authority citation for 21 CFR part 558 continues to read as follows:
4. In § 558.366, in paragraph (d), amend the table by:
a. Revising the entry for “90.8 to 181.6 (0.01 to 0.02 pct)”, and
b. Removing the entry for “Bacitracin methylene disalicylate 4 to 50” under the heading “113.5 (0.0125 pct)”; and
c. Removing the entry for “Bacitracin methylene disalicylate 50” under the heading “113.5 (0.0125 pct)”.
The additions and revisions read as follows:
(d) * * *
| Nicarbazin in grams per ton | Combination in grams per ton | Indications for use | Limitations | Sponsor |
|---|---|---|---|---|
| * * * * * * * | ||||
| 90.8 to 181.6 (0.01 to 0.02 pct) | Broiler chickens: As an aid in preventing outbreaks of cecal ( Eimeria tenella) and intestinal ( E. acervulina, E. maxima,E. necatrix, and E. brunetti) coccidiosis | Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard. Do not use as a treatment for coccidiosis. Do not feed to laying hens. Withdraw 4 days before slaughter for use levels at or below 113.5 g/ton. Withdraw 5 days before slaughter for use levels above 113.5 g/ton | 066104 | |
| Bacitracin methylene disalicylate 4 to 50 | Broiler chickens: As an aid in preventing outbreaks of cecal ( Eimeria tenella) and intestinal ( E. acervulina, E. maxima,E. necatrix, and E. brunetti) coccidiosis; for increased rate of weight gain and improved feed efficiency | Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard. Do not use as a treatment for coccidiosis. Do not feed to laying hens. Withdraw 4 days before slaughter for use levels at or below 113.5 g/ton. Withdraw 5 days before slaughter for use levels above 113.5 g/ton. Bacitracin methylene disalicylate as provided by No. 054771 in § 510.600(c) of this chapter | 054771 | |
| ( printed page 42008) | ||||
| Bacitracin methylene disalicylate 4 to 50 and roxarsone 22.7 to 45.4 | Broiler chickens: As an aid in preventing outbreaks of cecal ( Eimeria tenella) and intestinal ( E. acervulina, E. maxima, E. necatrix, and E. brunetti) coccidiosis; for increased rate of weight gain and improved feed efficiency | Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard. Do not use as a treatment for coccidiosis. Discontinue medication 5 days before marketing birds for human consumption. Do not feed to laying hens. Nicarbazin as provided by No. 066104; bacitracin methylene disalicylate and roxarsone as provided by No. 054771 in § 510.600(c) of this chapter | 066104 | |
| Bacitracin methylene disalicylate 30 | Broiler chickens: As an aid in preventing outbreaks of cecal ( Eimeria tenella) and intestinal ( E. acervulina, E. maxima,E. necatrix, and E. brunetti) coccidiosis; for increased rate of weight gain and improved feed efficiency | Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard. Do not use as a treatment for coccidiosis. Do not feed to laying hens. Withdraw 4 days before slaughter for use levels at or below 113.5 g/ton. Withdraw 5 days before slaughter for use levels above 113.5 g/ton. Bacitracin methylene disalicylate as provided by No. 054771 in § 510.600(c) of this chapter | 066104 | |
| Bacitracin methylene disalicylate 50 | Broiler chickens: As an aid in preventing outbreaks of cecal ( Eimeria tenella) and intestinal ( E. acervulina, E. maxima,E. necatrix, and E. brunetti) coccidiosis; as an aid in the prevention of necrotic enteritis caused or complicated by Clostridium spp. or other organisms susceptible to bacitracin | Feed continuously as sole ration from time chicks are placed on litter until past the time when coccidiosis is ordinarily a hazard. Do not use as a treatment for coccidiosis. Do not feed to laying hens. Withdraw 4 days before slaughter for use levels at or below 113.5 g/ton. Withdraw 5 days before slaughter for use levels above 113.5 g/ton. Bacitracin methylene disalicylate as provided by No. 054771 in § 510.600(c) of this chapter | 054771 | |
| * * * * * * * | ||||
5. In § 558.665, in the table, in paragraphs (e)(2), (e)(4), and (e)(6), revise the last sentence in the “Limitations” column and revise the “Sponsor” column to read as follows:
(e) * * *
| Zilpaterol in grams/ton | Combination in grams/ton | Indications for use | Limitations | Sponsor |
|---|---|---|---|---|
| * * * * * * * | ||||
| (2) | * * * Melengestrol acetate as provided by Nos. 000986 or 054771 in § 510.600(c) of this chapter | 000061 000986 | ||
| * * * * * * * | ||||
| (4) | * * * Monensin as provided by No. 000986; and melengestrol acetate as provided by Nos. 000986 or 054771 in § 510.600(c) of this chapter | 000061 000986 | ||
| * * * * * * * | ||||
| (6) | * * * Monensin as provided by No. 000986; tylosin as provided by Nos. 000986 or 016592; and melengestrol acetate as provided by Nos. 000986 or 054771 in § 510.600(c) of this chapter | 000061 000986 016592 | ||
Dated: July 1, 2013.
Bernadette Dunham,
Director, Center for Veterinary Medicine.
[FR Doc. 2013-16258 Filed 7-12-13; 8:45 am]
BILLING CODE 4160-01-P